InspireMD Inc. buy stratec
Start price
10.01.18
/
50%
€5,512.5
Target price
10.01.19
€13,388
Performance (%)
-98.00%
End price
10.01.19
€110.25
Summary
This prediction ended on 10.01.19 with a price of €110.25. Massive losses of -98.00% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| InspireMD Inc. | 0.000% | 0.000% | 41.176% | -49.260% |
| iShares Core DAX® | -1.816% | -2.419% | 12.070% | 14.356% |
| iShares Nasdaq 100 | 4.333% | 8.073% | 32.493% | 59.393% |
| iShares Nikkei 225® | 0.657% | 1.234% | 2.682% | 5.342% |
| iShares S&P 500 | 2.968% | 4.613% | 26.496% | 49.719% |
Comments by stratec for this prediction
In the thread InspireMD Inc. diskutieren
InspireMD expects Q4 2017 sales of ~$833K (+159%)
The company says the CGuard* stent is designed to prevent embolization (blocking a blood vessel) by
trapping potential emboli against the arterial wall while maintaining excellent blood flow.
* Das CGuardTM Embolic Prevention System (EPS) wurde entwickelt, um eine peri-prozedurale und späte Embolisation zu verhindern, indem mögliche Emboli gegen die Arterienwand abgefangen werden, während gleichzeitig eine ausgezeichnete Perfusion zu der äußeren Halsschlagader und den
Nebengefäßen aufrechterhalten wird.
(Laufzeit überschritten)